IkB alpha / NFKBIA Antibody ( FITC )

IkB alpha / NFKBIA Antibody Datasheet

IkB alpha / NFKBIA Antibody Product Information

• Immunogen: Recombinant Human IkB alpha / NFKBIA Protein (Catalog#12045-H07E)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 4H9G5
• Ig Type: Mouse IgG2b
• Concentration: 5 μl/Test, 0.2 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.1% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IkB alpha / NFKBIA (rh IkB alpha / NFKBIA; Catalog#12045-H07E; NP_065390.1; Phe 2-Leu 317) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

IkB alpha / NFKBIA Antibody Usage Guide

• Specificity: Human IkB alpha / NFKBIA
• Flow Cytometry: Fig 1, Fig 2. NFKBIA expression in HeLa and Jurkat cells.
  The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), and then stained with FITC Mouse anti-NFKBIA. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
  

  Fig 1. NFKBIA expression in HeLa cells

  

  Fig 2. NFKBIA expression in Jurkat cells

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Immunochemistry: ICC/IF: 5-20 μg/mL

  

  Immunofluorescence staining of human NFKBIA in HeLa cells with mouse monoclonal antibody (15 µg/mL). Primary antibody (FITC conjugated) was incubated for 1 hour at 37℃. The image showing nucleus staining of HeLa cells.

• Western blot: This antibody can be used at 1-2 μg/mL with the appropriate secondary reagents to detect Human NFKBIA in WB.
• Storage: This antibody is stable for 24 months from date of receipt when stored at 2℃- 8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

IkB alpha / NFKBIA Antibody Background

NF-kappa-B inhibitor alpha, also known as Major histocompatibility complex enhancer-binding protein MAD3, I-kappa-B-alpha, NFKBIA and IKBA, is a cytoplasm and nucleus protein which belongs to theNF-kappa-B inhibitor family. NFKBIA contains five ANK repeats. NFKBIA inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, NFKBIA becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to tranlocate to the nucleus and activate transcription. Defects in NFKBIA are the cause of ectodermal dysplasia anhidrotic with T-cell immunodeficiency autosomal dominant (ADEDAID). Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. ADEDAID is an ectodermal dysplasia associated with decreased production of pro-inflammatory cytokines and certain interferons, rendering patients susceptible to infection.

References

1. Scherer D.C. et al.,1995, Proc. Natl. Acad. Sci. USA. 92: 11259-11263.
2. Jungnickel B. et al., 2000, J. Exp. Med. 191: 395-402.
3. Courtois G. et al., 2003, J. Clin. Invest. 112: 1108-1115.
4. Ota T. et al., 2004, Nat. Genet. 36: 40-45.